Bio-Rad Laboratories Class A

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO and other ETFs, options, and stocks.

About BIO

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics.

CEO

Norman D. Schwartz

CEONorman D. Schwartz

Employees

7,450

Employees7,450

Headquarters

Hercules, California

HeadquartersHercules, California

Founded

1952

Founded1952

Employees

7,450

Employees7,450

BIO Key Statistics

Market cap

8.47B

Market cap8.47B

Price-Earnings ratio

52.38

Price-Earnings ratio52.38

Dividend yield

—

Dividend yield—

Average volume

545.67K

Average volume545.67K

High today

$319.50

High today$319.50

Low today

$311.85

Low today$311.85

Open price

$311.85

Open price$311.85

Volume

165.26K

Volume165.26K

52 Week high

$343.12

52 Week high$343.12

52 Week low

$211.43

52 Week low$211.43

Stock Snapshot

Bio-Rad Laboratories Class A(BIO) stock is priced at $315.57, giving the company a market capitalization of 8.47B. It carries a P/E multiple of 52.38.

During the trading session on 2026-05-29, Bio-Rad Laboratories Class A(BIO) shares reached a daily high of $319.50 and a low of $311.85. At a current price of $315.57, the stock is +1.2% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 165.26K, compared to an average daily volume of 545.67K.

Over the past 52 weeks, Bio-Rad Laboratories Class A(BIO) stock has traded between a high of $343.12 and a low of $211.43.

BIO News

Simply Wall St 3d

How Investors May Respond To Bio-Rad Laboratories Facing Elliott’s Activist Push Over Sartorius Stake

On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing the company to address what it describes...

TipRanks 4d

Bio-Rad price target raised to $310 from $290 at Wells Fargo

Wells Fargo raised the firm’s price target on Bio-Rad (BIO) to $310 from $290 and keeps an Equal Weight rating on the shares after meeting with management. The...

Simply Wall St 6d

Is It Time To Reassess Bio-Rad Laboratories After Its Recent 16% Weekly Surge?

If you are wondering whether Bio-Rad Laboratories at around US$287.74 is priced attractively or not, it helps to step back and look at what the recent share per...

Analyst ratings

57%

of 7 ratings

Buy

28.6%

Hold

57.1%

Sell

14.3%

People also own

Based on the portfolios of people who own BIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.